RxDoctor Payments Data

Tri Te

Interventional Cardiology · Las Vegas, NVNPI 1447632971

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medtronic at 29.8% of the total. Reporting peaked in 2023 at $2,544 and has fallen 65.8% since, to $871 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NV, where the typical reported total is $9,708.

$8,891in general payments, 2019–2025

Across 101 payments — averaging $88.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$2K
  • Penumbra, Inc.$2K
  • AstraZeneca$705
  • Boston Scientific$575
  • Abiomed$571
  • plus $826 from 12 others

What the payments were for

  • Travel & lodging$3,49739%
  • Food & beverage$4,50751%
  • Education$88710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,891 in reported general payments places this provider in the 45th percentile of 62 interventional cardiology providers in Nevada.

See all interventional cardiology providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor11$10,897
ClopidogrelClopidogrel Bisulfate56$696
Atorvastatin Calcium28$174
Rosuvastatin Calcium11$141
Metoprolol Succinate18$106
Nitroglycerin15$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$705$10,89711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 62 interventional cardiology providers in Nevada.

Other interventional cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →